Skip to main content
Top
Literature
1.
go back to reference Smith EP (2010) Hematological disorders after solid organ transplantation. Hematology Am Soc Hematol Educ Program 2010:281–286PubMed Smith EP (2010) Hematological disorders after solid organ transplantation. Hematology Am Soc Hematol Educ Program 2010:281–286PubMed
2.
go back to reference Audet M, Panaro F, Piardi T, Huang P, Cag M, Cinqualbre J et al (2008) Passenger lymphocyte syndrome and liver transplantation. Clin Dev Immunol 2008:1–4CrossRef Audet M, Panaro F, Piardi T, Huang P, Cag M, Cinqualbre J et al (2008) Passenger lymphocyte syndrome and liver transplantation. Clin Dev Immunol 2008:1–4CrossRef
4.
go back to reference Romero S, Solves P, Lancharro A, Cano I, Moscardo F, Carpio N et al (2015) Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases. Blood Transfus 13(3):423–428PubMedPubMedCentral Romero S, Solves P, Lancharro A, Cano I, Moscardo F, Carpio N et al (2015) Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases. Blood Transfus 13(3):423–428PubMedPubMedCentral
5.
go back to reference Yazer MH, Triulzi DJ (2007) Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 14(6):664–670CrossRefPubMed Yazer MH, Triulzi DJ (2007) Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 14(6):664–670CrossRefPubMed
Metadata
Title
Passenger Lymphocyte Syndrome Following Minor ABO Mismatch Liver Transplantation
Authors
Deepti Sachan
Suryatapa Saha
Srinivas M. Reddy
Mohamed Rela
Publication date
01-10-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-0971-8

Other articles of this Issue 4/2018

Indian Journal of Hematology and Blood Transfusion 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine